×
To start your customized experience click the start button
Customize ?  
Start
Cancer Types
Quick Links
Award Programs
About Us
Careers
Contact Us
Newsroom
Privacy Policy
Terms & Conditions
 
Twitter
Face Book
YouTube
Instagram
 
 
Cure Media Group, LLC.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873

Copyright © 2018
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.

Mantle Cell Lymphoma

Kristie L. Kahl
Lawrence D. Kaplan, M.D., discusses recent updates and next steps to be taken in Hodgkin, mantle cell and follicular lymphoma.
 
Kristie L. Kahl
Entospletinib monotherapy yielded limited activity in patients with relapsed or refractory indolent non-Hodgkin lymphoma and mantle cell lymphoma.
Katie Kosko
Imbruvica (ibrutinib) is a safe treatment for patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and mantle cell lymphoma (MCL), according to a pooled analysis of four clinical trials.
 
Kristie L. Kahl
The replacement of vincristine with Velcade (bortezomib) in the R-CHOP regimen for the treatment of transplantation-ineligible patients with newly diagnosed mantle cell lymphoma improved overall survival in a final analysis of the LYM-3002 trial.
 
Kristie L. Kahl
A blood test may help to identify a subset of patients with mantle cell lymphoma and determine the management of outcomes of these individuals.
 
Brielle Urciuoli
New drug regimens are not only personalizing the treatment of patients with mantle cell lymphoma, but they’re also improving outcomes, too, explained Chaitra S. Ujjani, M.D.
Bijal D. Shah, M.D.
A certain group of patients may not be candidates for common therapies, explained Bijal D. Shah, M.D.
Brielle Urciuoli
This infographic explains some of the basics on mantle cell lymphoma, a type of non-Hodgkin lymphoma.
Kevin Berry
One of the things I think about is the future. All cancer patients know we have two futures: One where things go well, and one where they don't.
Brielle Urciuoli
Deferring treatment may actually be beneficial for some patients with mantle cell lymphoma (MCL), according to recent research.
×
×

Sign In

Not a member? Sign up now!
Continue without login
Continue
×

Sign Up

Patient Caregiver Advocate Other